Interstitial nephritis secondary prevention

Jump to navigation Jump to search

Interstitial nephritis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Interstitial nephritis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Interstitial nephritis secondary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Interstitial nephritis secondary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Interstitial nephritis secondary prevention

CDC on Interstitial nephritis secondary prevention

Interstitial nephritis secondary prevention in the news

Blogs on Interstitial nephritis secondary prevention

Directions to Hospitals Treating Interstitial nephritis

Risk calculators and risk factors for Interstitial nephritis secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief:Mohsen Basiri M.D.

Overview

The mainstay preventive action is to stay away from re-exposure to the offensive agents of the acute episode. Among patients with chronic inflammatory diseases such as Sjogren's syndrome, sarcoidosis, or SLE, proper control of the underlying condition alongside with consideration of offensive agent is important and should be kept in mind.

Secondary Prevention

The mainstay preventive action is to stay away from exposure to the offensive agents of the acute episode. If the culprit drug has clearly been identified, then avoiding future use of the medication is recommended, because AIN may recur on re-exposure to the original antigen. Where known cross-reactivity exists, for example between penicillins and cephalosporins, the risk of using a related agent should be carefully weighed against the benefit of using it. If such an agent is used, the patient should be appropriately monitored for any side effects. For patients with chronic inflammatory diseases such as Sjogren's syndrome, sarcoidosis, or SLE, proper control of the underlying condition alongside with consideration of offensive agent is important.

References

Template:WH Template:WS